Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SLO-PHYLLIN vs AMINOPHYLLINE DYE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., COPD, emphysema, chronic bronchitis),Off-label: Apnea of prematurity,Off-label: Adjunctive therapy in acute asthma exacerbations (rarely used)
Treatment of bronchospasm associated with asthma, chronic bronchitis, emphysema, and COPD,Apnea of prematurity (off-label)
Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
Terminal elimination half-life is approximately 3-8 hours in adults (non-smokers, healthy), 1-5 hours in smokers, and 20-30 hours in neonates. Clinical context: Half-life is prolonged in hepatic cirrhosis, heart failure, and with certain drug interactions (e.g., cimetidine, ciprofloxacin).
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Primarily hepatic via CYP450 enzymes: CYP1A2, CYP2E1, CYP3A4; metabolite: 1,3-dimethyluric acid. Approximately 10% excreted unchanged in urine.
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4, CYP2E1, and CYP2D6. Metabolism may be saturated, leading to nonlinear kinetics at therapeutic doses.
Renal: ~10% unchanged; hepatic metabolism accounts for ~90% of elimination, with metabolites excreted in urine. Fecal: <5%.
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
Approximately 40% bound to albumin; binding is saturable and decreased in neonates, hepatic disease, and acidosis.
Approximately 40% bound, primarily to albumin. In neonates, protein binding is lower (about 30%).
0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Distributes evenly into body water and highly perfused tissues; Vd increased in premature infants and decreased in obesity.
Approximately 0.5 L/kg (range 0.3-0.7 L/kg). Higher in premature infants and neonates (0.6-0.9 L/kg). Vd corresponds to total body water; aminophylline distributes into extracellular and intracellular fluid.
Oral immediate-release: 96-100%; oral sustained-release (Slo-Phyllin): 90-100% relative to immediate-release; rectal: variable (~80-100% for enema); IV: 100%.
Oral immediate-release: nearly 100%. Oral sustained-release: 80-100% depending on formulation. Rectal: variable (80-100%). Intravenous: 100%.
No specific dose adjustment is required for renal impairment. However, monitoring serum concentrations is recommended due to altered clearance in severe renal failure (GFR <10 m L/min).
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min: reduce dose by 50% and monitor serum theophylline levels closely.
Child-Pugh Class B or C: Reduce dose by 50% and monitor serum concentrations closely. Avoid use in severe hepatic impairment if possible.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: use alternative therapy or reduce dose by 80-90% with close monitoring.
Starting dose: 5 mg/kg/day orally in divided doses every 6 hours (immediate-release) or every 12 hours (sustained-release). Titrate based on serum concentrations, targeting 5-15 mcg/m L. Maximum dose: 24 mg/kg/day or 900 mg/day, whichever is less.
Loading dose: 5-6 mg/kg IV over 30 minutes. Maintenance IV infusion: age 1-6 months: 0.5 mg/kg/hour; 6-12 months: 0.6-0.7 mg/kg/hour; 1-9 years: 0.8-1.0 mg/kg/hour; >9 years: 0.5-0.7 mg/kg/hour. Oral: 5-6 mg/kg every 6 hours (immediate-release) or every 12 hours (extended-release).
Start at low end of dosing range (e.g., 200-300 mg/day sustained-release). Monitor serum concentrations carefully as clearance is reduced in elderly patients, increasing risk of toxicity.
Lower initial doses recommended (e.g., 300-400 mg/day oral) with slower titration, as clearance is decreased. Monitor serum theophylline levels and adjust to achieve 5-15 mcg/m L.
No FDA boxed warning.
Theophylline has a narrow therapeutic index; serum levels must be monitored. Severe toxicity can occur at levels above 20 mcg/m L, including seizures, cardiac arrhythmias, and death. Use with caution as serious adverse effects may occur without warning.
Concurrent illness (fever, influenza), hepatic impairment, elderly, and smoking alter metabolism; narrow therapeutic index (10-20 mcg/m L); monitor serum levels; risk of seizures, arrhythmias, and death with toxicity; reduce dose with CYP1A2 inhibitors (cimetidine, fluoroquinolones, macrolides) or inducers (smoking, rifampin, phenytoin); caution in peptic ulcer disease, seizure disorders, cardiac arrhythmias.
Monitor serum theophylline levels; adjust dose accordingly,Risk of toxicity is increased in patients with hepatic impairment, congestive heart failure, cor pulmonale, and elderly patients,May exacerbate or induce peptic ulcer disease, seizures, and other cardiac arrhythmias,Concurrent use with other xanthines can increase toxicity,Smoking cessation decreases clearance and may require dose reduction
Hypersensitivity to theophylline or any component,Pre-existing arrhythmia (especially tachyarrhythmias),Active seizure disorder not adequately controlled
Hypersensitivity to theophylline or any component,Active seizure disorder unless adequately controlled with medications,Severe cardiac arrhythmias (e.g., ventricular tachycardia),Pregnancy (controversial; use only if clearly needed)
Avoid high-fat meals as they may alter absorption of sustained-release preparations. Limit caffeine-containing foods and beverages. Avoid charcoal-broiled foods, which can increase metabolism.
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. High-fat meals may slow absorption of extended-release formulations. No other significant food interactions.
Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester exposure is not associated with major congenital malformations. Third trimester use may lead to transient neonatal apnea, jitteriness, or tachycardia due to placental transfer. No increased risk of preterm birth or low birth weight has been consistently demonstrated.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of fetal tachycardia, jitteriness, and hypoglycemia due to maternal theophylline levels; no clear teratogenic signal. Close monitoring recommended.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach therapeutic concentrations if maternal doses are high. Breastfeeding is generally considered compatible, but monitor the infant for signs of theophylline toxicity (e.g., irritability, insomnia, tachycardia).
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant serum levels are typically subtherapeutic, but irritability, jitteriness, and feeding intolerance have been reported. Caution advised; monitor infant for adverse effects. Benefit-risk assessment required.
Pregnancy may decrease theophylline clearance by 20-30%, particularly in the third trimester, due to reduced hepatic metabolism. Dose adjustments may be needed to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; reduce dose accordingly to avoid toxicity.
Pregnancy increases theophylline clearance by 20-40% due to increased hepatic metabolism and renal blood flow. Monitor serum levels and adjust dose to maintain therapeutic range. Consider extended-release formulations for stable levels. Postpartum: clearance may decrease rapidly, requiring dose reduction.
Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Adjust dose in patients with heart failure, liver disease, or on CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Do not crush or chew sustained-release tablets. Cigarette smoking induces metabolism, requiring higher doses.
Aminophylline is a bronchodilator that contains theophylline and ethylenediamine. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Avoid use in patients with active peptic ulcer disease. Ethylenediamine component may cause allergic reactions in sensitive patients. Dose adjustment required in hepatic impairment, heart failure, or elderly. Tachyphylaxis may occur with prolonged use. Cigarette smoking increases clearance; monitor levels closely. Consider drug interactions with cimetidine, fluoroquinolones, and macrolides which decrease clearance.
Take this medication exactly as prescribed, usually every 8-12 hours.,Do not crush or chew the tablets; swallow them whole.,Avoid excessive caffeine intake (coffee, tea, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, or irregular heartbeat.,Do not change brands or formulations without consulting your doctor.
Do not chew or crush extended-release tablets; swallow whole.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity such as nausea, vomiting, insomnia, rapid heartbeat, or seizures immediately.,Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Inform your doctor if you have a history of seizures, ulcers, or liver disease.,Do not smoke or stop smoking without medical advice as it affects how this medication works.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SLO-PHYLLIN vs AMINOPHYLLINE DYE FREE, answered by our medical review team.
SLO-PHYLLIN is a Xanthine Bronchodilator that works by SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.. AMINOPHYLLINE DYE FREE is a Xanthine Bronchodilator that works by Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SLO-PHYLLIN and AMINOPHYLLINE DYE FREE depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SLO-PHYLLIN is: Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of AMINOPHYLLINE DYE FREE is: Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SLO-PHYLLIN and AMINOPHYLLINE DYE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SLO-PHYLLIN is classified as Category C. Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester expos. AMINOPHYLLINE DYE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.